Skip to main content
SpringerLink
Log in

First-line EGFRI not cost effective for metastatic colorectal cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. fluorouracil + folinic acid (leucovorin) + irinotecan

  2. fluorouracil + folinic acid + oxaliplatin

  3. 2012 Canadian dollars

References

  1. Riesco-Martinez MC, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of Oncology Practice : 3 May 2016. Available from: URL: http://doi.org/10.1200/JOP.2015.008730

    PubMed  Google Scholar 

  2. Goldstein DA. Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the Bathwater. Journal of Oncology Practice : 3 May 2016. Available from: URL: http://doi.org/10.1200/JOP.2016.011460

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-line EGFRI not cost effective for metastatic colorectal cancer. PharmacoEcon Outcomes News 753, 15 (2016). https://doi.org/10.1007/s40274-016-3048-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3048-7

Search

Navigation